Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

John Memmott

Yuliya Kutskova

Chung-Ming Hsieh

Jennifer Maria Perez

Anca Clabbers

Suju Zhong

Margaret Hugunin

Edit Tarcsa

Bradford L McRae

Mary Leddy

Anwar Murtaza

Craig Wallace

Shaughn H Bryant

Lorenzo Benatuil

Bernhard K Mueller

Philip D Bardwell

Lili Huang

Alyssa Brito

Michael Roguska

Steven Grant

Ian M Tomlinson

Mihriban Tuna

Emma Fung

Carrie Goodreau

Jacqueline G Bixby

Wendy Waegell

Sahana Bose

Lucia Eaton

Alexander Ivanov

Carrie Enever

Provided herein are anti-Repulsive Guidance Molecule a (RGMa) antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof

Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-&#x3b1;), e.g., human TNF-&#x3b1;, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Immunobinders directed against TNF

Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

IL-17 binding proteins

Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

Bispecific antibodies directed against TNF-&#x3b1; and IL-17

Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

Antibodies that bind to repulsive guidance molecule A (RGMA)

Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration

Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.

Immunobinders directed against sclerostin

The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.

Methods of RNA display

Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.

Antibody libraries

The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1&#x3b1; and human IL-1&#x3b2;. The dual specific antibodies of the invention also neutralize both human IL-1&#x3b1; and human IL-1&#x3b2;. The invention also provides domain antibodies (dAbs) specific for human IL-1&#x3b1; and human IL-1&#x3b2;.

Growing community of inventors

Framingham, MA, United States of America

John Memmott